The Industry’s Environmental Challenge
Pharmaceutical manufacturing is resource intensive. Organic synthesis generates solvent waste. GMP facilities consume significant energy for temperature and humidity control. Global clinical supply chains generate carbon through international shipping. For an industry that exists to improve human health, the environmental cost of drug production is an increasingly visible contradiction.
This tension is not new, but the pressure to address it has accelerated significantly. Investor ESG frameworks, regulatory agency guidance on environmental risk assessment, and the industry’s own sustainability commitments are all pushing pharmaceutical companies and their outsourcing partners towards greener manufacturing practices. The American Chemical Society’s 12 Principles of Green Chemistry provide a widely used framework for evaluating and improving the environmental performance of chemical processes.
Where Green Chemistry Applies in Drug Development
Solvent Selection and Recovery
Solvents account for a significant proportion of the waste generated in pharmaceutical synthesis. Green chemistry approaches prioritise the use of less hazardous solvents, the recovery and recycling of solvents where technically feasible, and the substitution of traditional solvents with greener alternatives from established solvent selection guides. Several regulatory agencies now expect sponsors to address solvent choice in their CMC narratives.
Process Efficiency and Atom Economy
Atom economy, the proportion of the atoms in the starting materials that end up in the final product, is a core green chemistry metric for synthetic routes. A route with high atom economy generates less waste per kilogram of product and typically requires fewer purification steps. Evaluating synthetic routes against green chemistry metrics during process development, rather than at scale-up, reduces the cost of improvement.
Energy Intensity in GMP Manufacturing
Heating, cooling, and environmental control systems in GMP facilities are major energy consumers. Equipment upgrades, heat recovery systems, and process optimisation to reduce cycle times all contribute to reducing energy intensity per batch. For manufacturers working with thermolabile products, the energy cost of cold chain storage and distribution is an additional area of focus.
Green Chemistry Metrics in Pharmaceutical Development
| Metric | What It Measures | Industry Benchmark |
| Process Mass Intensity (PMI) | Total mass in divided by mass of product | Industry mean: 200-300 for drug substance; target below 100 |
| E-factor | Mass of waste per mass of product | Fine chemicals: 5-50; pharmaceuticals: 25-100 |
| Solvent intensity | Solvent mass per kg of API | Reduction targets vary by synthesis complexity |
| Carbon footprint per batch | CO2 equivalent across utilities and logistics | Measured against baseline year; reduction targets per ESG policy |
Note: industry benchmarks cited above are drawn from published ACS Green Chemistry and Pharmaceutical Roundtable data and represent general ranges rather than regulatory requirements.
Ardena’s Approach to Sustainable Manufacturing
Ardena is committed to reducing the environmental impact of its manufacturing operations across all sites. In chemical synthesis, this includes evaluating solvent selection as part of process development, with a preference for solvents in the preferred and usable categories of established selection guides. Process analytical technology (PAT) tools used in Ardena’s manufacturing facilities contribute to reduced waste by enabling real-time release and reducing the need for rework.
For biotech companies with sustainability commitments to their investors or stakeholders, partnering with a CDMO that takes environmental performance seriously is an increasingly practical requirement. Ardena’s scientific teams are happy to discuss process development approaches that align with your organisation’s green chemistry objectives.
